Nathan brings almost 25 years of industry and drug development experience from early clinical stage to commercialization, including the authorship of regulatory submissions ranging from IND and IMPD initial filings, CMC amendments, technical questions for FDA meeting requests, and the evaluation and management of domestic and international CROs and CMOs. Previously, Nathan was senior director of chemical development and director of chemistry, manufacturing and controls at Global Blood Therapeutics, where he was a key contributor to the marketed product Voxelotor and managed all CMC aspects of the pre-IND hereditary angioedema program. Prior to GBT, Nathan served numerous roles at Exelixis, where he made key contributions to the commercialization of Cometriq and a team leader for the Genentech collaboration with Exelixis for cobimetinib. Nathan received his Ph.D. for organic chemistry from Colorado State University and completed his postdoctoral work at University of Colorado in total synthesis and asymmetric acetate aldol methodology.
